115 related articles for article (PubMed ID: 2891184)
1. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis.
Eriksson LS; Brundin T; Söderlund C; Wahren J
Scand J Gastroenterol; 1987 Oct; 22(8):919-25. PubMed ID: 2891184
[TBL] [Abstract][Full Text] [Related]
2. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis.
Wahren J; Eriksson LS
Scand J Gastroenterol Suppl; 1986; 119():103-8. PubMed ID: 2876492
[TBL] [Abstract][Full Text] [Related]
3. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis.
Pringle SD; McKee RF; Garden OJ; Lorimer AR; Carter DC
Aliment Pharmacol Ther; 1988 Oct; 2(5):451-9. PubMed ID: 2979267
[TBL] [Abstract][Full Text] [Related]
4. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man.
Jenkins SA; Baxter JN; Corbett WA; Shields R
Br J Surg; 1985 Dec; 72(12):1009-12. PubMed ID: 2867802
[TBL] [Abstract][Full Text] [Related]
5. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis.
Eriksson LS; Law DH; Sato Y; Wahren J
Clin Physiol; 1984 Feb; 4(1):5-11. PubMed ID: 6141861
[TBL] [Abstract][Full Text] [Related]
6. The effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the cirrhotic rat.
Jenkins SA; Baxter JN; Corbett WA; Shields R
Br J Surg; 1985 Nov; 72(11):864-7. PubMed ID: 2866012
[TBL] [Abstract][Full Text] [Related]
7. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects.
Sonnenberg GE; Keller U; Perruchoud A; Burckhardt D; Gyr K
Gastroenterology; 1981 Mar; 80(3):526-32. PubMed ID: 6108898
[TBL] [Abstract][Full Text] [Related]
8. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
Bosch J; Kravetz D; Rodes J
Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
[TBL] [Abstract][Full Text] [Related]
9. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis.
Møller S; Brinch K; Henriksen JH; Becker U
J Hepatol; 1997 May; 26(5):1026-33. PubMed ID: 9186833
[TBL] [Abstract][Full Text] [Related]
10. Changes of hepatic and systemic haemodynamics following somatostatin administration in patients with hepatitis B-related cirrhosis.
Hsia HC; Lin HC; Lee FY; Tsai YT; Lee SD; Meng HC; Chao Y; Wang SS; Lo KJ
J Gastroenterol Hepatol; 1993; 8(1):15-20. PubMed ID: 8094983
[TBL] [Abstract][Full Text] [Related]
11. Effects of somatostatin on hepatic haemodynamics in the cirrhotic rat.
Jenkins SA; Devitt P; Day DW; Baxter JN; Shields R
Digestion; 1986; 33(3):126-34. PubMed ID: 2868955
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects.
Eriksson LS; Wahren J
Eur J Clin Invest; 1989 Apr; 19(2):213-9. PubMed ID: 2499481
[TBL] [Abstract][Full Text] [Related]
13. The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients.
Ottesen LH; Flyvbjerg A; Møller S; Bendtsen F
Aliment Pharmacol Ther; 1998 Jul; 12(7):657-65. PubMed ID: 9701530
[TBL] [Abstract][Full Text] [Related]
14. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation.
Cirera I; Feu F; Luca A; García-Pagán JC; Fernández M; Escorsell A; Bosch J; Rodés J
Hepatology; 1995 Jul; 22(1):106-11. PubMed ID: 7601400
[TBL] [Abstract][Full Text] [Related]
15. Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease.
Matrella E; Valatas V; Notas G; Roumpaki H; Xidakis C; Hadzidakis A; Mouzas I; Kouroumalis E
Aliment Pharmacol Ther; 2001 Jun; 15(6):857-64. PubMed ID: 11380324
[TBL] [Abstract][Full Text] [Related]
16. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension.
Cerini R; Lee SS; Hadengue A; Koshy A; Girod C; Lebrec D
Gastroenterology; 1988 Mar; 94(3):703-8. PubMed ID: 2892752
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure.
Jenkins SA; Nott DM; Baxter JN
HPB Surg; 1998; 11(1):13-21. PubMed ID: 9830576
[TBL] [Abstract][Full Text] [Related]
18. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension.
Merkel C; Gatta A; Zuin R; Finucci GF; Nosadini R; Ruol A
Digestion; 1985; 32(2):92-8. PubMed ID: 2864299
[TBL] [Abstract][Full Text] [Related]
19. Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis.
Lin HC; Tsai YT; Huang CC; Meng HC; Lee FY; Wang SS; Lee SD; Lo KJ
J Hepatol; 1994 Sep; 21(3):424-9. PubMed ID: 7836713
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral propranolol on splanchnic oxygen uptake and haemodynamics in patients with cirrhosis.
Bendtsen F; Henriksen JH; Becker U; Sørensen TI
J Hepatol; 1987 Oct; 5(2):137-43. PubMed ID: 3693857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]